SCHEMBL1554635

SCHEMBL1554635

Cc1ccc(-c2csc(N3C(=O)c4ccccc4C3=O)c2C(=O)O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.48
KMT2A Q03164 8/20 0.48
NPC1 O15118 4/20 0.48
AR P10275 1/20 0.48
RAB9A P51151 3/20 0.44
GRIN2C Q14957 1/20 0.44
ALDH1A1 P00352 6/20 0.43
MAPT P10636 3/20 0.43
MAPK1 P28482 2/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
POLB P06746 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
PKM P14618 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
PRNP P04156 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1554791 0.92 ALDH1A1 (0.46) MEN1KMT2ANPC1ARRAB9A
SCHEMBL1553831 0.88 MEN1 (0.46) MEN1KMT2ANPC1ARRAB9A
SCHEMBL1553923 0.88 AR (0.49) MEN1KMT2ANPC1ARRAB9A
SCHEMBL1553944 0.88 POLB (0.44) MEN1KMT2ANPC1ARALDH1A1
SCHEMBL1553601 0.87 ALDH1A1 (0.42) MEN1KMT2ANPC1ALDH1A1MAPT
SCHEMBL1554744 0.87 HSD17B10 (0.47) MEN1KMT2ANPC1ARALDH1A1
SCHEMBL4563209 0.87 KMT2A (0.42) MEN1KMT2ANPC1RAB9AGRIN2C
SCHEMBL1553395 0.87 AR (0.52) MEN1KMT2ANPC1ARGRIN2C
SCHEMBL1553883 0.84 ALDH1A1 (0.55) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL3972241 0.84 MEN1 (0.46) MEN1KMT2ANPC1RAB9AGRIN2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383463-B1 FUSED THIOPHENE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF CHRONIC PAIN KING PHARMACEUTICALS INC (US) 2011-04-27 EP disclosed
EP-1383463-A4 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE KING PHARMACEUTICALS INC (US) 2009-03-25 EP disclosed
US-7449490-B2 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2008-11-11 US disclosed
US-7101905-B2 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2006-09-05 US disclosed
US-20060183921-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2006-08-17 US disclosed
EP-1383463-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE King Pharmaceuticals, Inc. (US) 2004-01-28 EP disclosed
US-20030073733-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2003-04-17 US disclosed
WO-2002083083-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE KING PHARMACEUTICALS, INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183921-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE MEN1 4077/4885KMT2A 4595/4885NPC1 931/4885
US-20030073733-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE MEN1 4077/4885KMT2A 4595/4885NPC1 931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.